Anti-CD19
CAR T as a feasible and safe therapy for refractory/relapsed mixed
phenotype acute leukemia (MPAL) patients
Xiangqun Li1Ⅰ
Kylan Chen2Ⅰ Hailong Zhang1Ⅰ Xian
Zhang3,4Ⅰ Junfang Yang3,4Ⅰ Jing
Liu1Ⅰ Jianwei Zheng1Ⅰ Fei
Dong1, Yongbo Zhu1Ⅰ Jiao
Yu1Ⅰ Haihong Zhang1Ⅰ Peihua
Lu3,4Ⅰ Bo Chen1
1 Kecellitics
Biotech Company Ltd, Beijing, China
2 College of Natural Sciences, University of Texas
3 Lu Daopei Hospital, Langfang, Hebei, China4 Lu Daopei Institute of Hematology, Beijing, China